Results 181 to 190 of about 658,178 (349)

Corticosteroids for alcoholic hepatitis—what's next? [PDF]

, 2005
Philippe Mathurin
openalex   +1 more source

Mitochondrial dysfunction: Related diseases, influencing factors, and detection

Interdisciplinary Medicine, EarlyView.
Mitochondrial dysfunction is implicated in the pathogenesis of numerous diseases, including neurological disorders, cancers, and cardiovascular conditions, through mechanisms such as mitochondrial DNA mutations, dysregulation of mitochondrial network dynamics, and impaired mitophagy.
Zhaojin Li, Shiyu Li, Wanying Chen, Ziyu Zhang, Chun Pan, Peng Lei, Cheng Cheng, Junyou Zhu, Hanxiao Sun, Zhenning Dai   +9 more
wiley   +1 more source

Narrative Review: Glucocorticoids in Alcoholic Hepatitis-Benefits, Side Effects, and Mechanisms. [PDF]

J Xenobiot, 2022
Lu H.
europepmc   +1 more source

Review article: non‐alcoholic fatty liver disease and hepatitis C – risk factors and clinical implications [PDF]

, 2005
Arun J. Sanyal
openalex   +1 more source

Roles of nanomagnetic beads on biosensing: From fabrication to application

Interdisciplinary Medicine, EarlyView.
Leveraging their intrinsic superparamagnetic properties and rapid magnetic responsiveness, functionalized nanomagnetic beads have emerged as pivotal platforms in advanced biosensing system. Through surface engineering and structural design, these magnetic nanoparticles demonstrate multi‐capabilities, such as sample separation, signal enhancement, and ...
Junjie Li, Liyang Duan, Qian Chen, Songsong Huang, Weixia Li, Huachu Zuo, Shuang Li, Wei Han, Wei Fu, Shike Hou, Bin Fan, Zetao Chen   +11 more
wiley   +1 more source

Epigenetic therapy for alcoholic hepatitis: can larsucosterol change the treatment landscape? [PDF]

Ann Med Surg (Lond)
Fatima F, Fatima M, Raza A, Ahmad B, Akilimali A.   +4 more
europepmc   +1 more source

Severe type alcoholic hepatitis.

, 1998
Shujiro Takase
openalex   +2 more sources

Is alcoholic hepatitis an indication for transplantation? Current management and outcomes [PDF]

, 2005
Philippe Mathurin
openalex   +1 more source

Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease

The Journal of Clinical Pharmacology, EarlyView.
Abstract Fenofibrate is contraindicated in patients with advanced hepatic fibrosis due to limited clinical data. We evaluated the pharmacokinetics and safety of fenofibrate in participants with mild hepatic impairment (phase 1 study) or advanced fibrosis due to metabolic‐associated fatty liver disease (MAFLD; phase 2a study).
Islam R. Younis, Elijah J. Weber, Cara Nelson, Ann R. Qin, Timothy R. Watkins, Ahmed A. Othman   +5 more
wiley   +1 more source

Prognostic challenges in alcoholic hepatitis: From scoring systems to clinical predictors. [PDF]

World J Hepatol
Ramírez-Mejía MM, Morales-Galicia AE, Méndez-Sánchez N.   +2 more
europepmc   +1 more source